The first placebo-controlled trial in cryopyrin-associated periodic syndromes (CAPS): IL-1 trap (rilonacept) markedly reduces clinical and laboratory abnormalities in patients with familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS)

[摘要]

[发布日期] 2007-02-01